The Phase 3 clinical trial to explore the safety and efficacy of UGN-104 is ongoing and is expected to be fully enrolled by the end of 2026. UGN-104 is a next-generation mitomycin product for LG-UTUC.

Earnest has built a strong reputation as one of the top student loan lenders in the country. With more than $24 billion in student loans refinanced and over 420,000 clients served, the company has ...

Debt relief could make it easier to pay off your balances, but any overlooked costs could cancel out the savings.

Troubles are coming to the European economy. These could precipitate a European economic recession and cause serious debt ...

Forever chemicals don't break down and don't disappear, but Florida International University scientists have developed a safer, cheaper, and reusable solution that could remove these chemicals. FIU ...

Arsenic contamination in drinking water is a global issue, with over 200 million people estimated to be at risk. While water treatment plants remove the metal, the problem persists in low-resource ...

The European chemicals industry has entered a sustained period of pressure characterised by excess global capacity, subdued end‑market demand, structurally higher energy and compliance costs relative ...

Removing paint from concrete from a wall or a floor may seem like an impossible task. However, there is a quick and easy way that not only removes the paint almost like it was never there, but it ...

A new study shows that carefully designed biochar can effectively remove harmful “forever chemicals” from recycled water used in agriculture, offering a promising and sustainable solution to protect ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. The level and widespread nature of medical debt in the United ...

The U.S. is now $39 trillion in debt. Politicians have been fighting over the federal spending for decades and even briefly balanced the budget at the end of then-President Bill Clinton’s term. But ...